1. Isoform-selective TGF-β3 inhibition for systemic sclerosis.
- Author
-
Sun T, Vander Heiden JA, Gao X, Yin J, Uttarwar S, Liang WC, Jia G, Yadav R, Huang Z, Mitra M, Halpern W, Bender HS, Brightbill HD, Wu Y, Lupardus P, Ramalingam T, and Arron JR
- Subjects
- Humans, Transforming Growth Factor beta1 metabolism, Transforming Growth Factor beta2 metabolism, Fibrosis, Protein Isoforms metabolism, Transforming Growth Factor beta3 metabolism, Scleroderma, Systemic drug therapy
- Abstract
Background: Transforming growth factor β (TGF-β) is implicated as a key mediator of pathological fibrosis, but its pleiotropic activity in a range of homeostatic functions presents challenges to its safe and effective therapeutic targeting. There are three isoforms of TGF-β, TGF-β1, TGF-β2, and TGF-β3, which bind to a common receptor complex composed of TGF-βR1 and TGF-βR2 to induce similar intracellular signals in vitro. We have recently shown that the cellular expression patterns and activation thresholds of TGF-β2 and TGF-β3 are distinct from those of TGF-β1 and that selective short-term TGF-β2 and TGF-β3 inhibition can attenuate fibrosis in vivo without promoting excessive inflammation. Isoform-selective inhibition of TGF-β may therefore provide a therapeutic opportunity for patients with chronic fibrotic disorders., Methods: Transcriptomic profiling of skin biopsies from patients with systemic sclerosis (SSc) from multiple clinical trials was performed to evaluate the role of TGF-β3 in this disease. Antibody humanization, biochemical characterization, crystallization, and pre-clinical experiments were performed to further characterize an anti-TGF-β3 antibody., Findings: In the skin of patients with SSc, TGF-β3 expression is uniquely correlated with biomarkers of TGF-β signaling and disease severity. Crystallographic studies establish a structural basis for selective TGF-β3 inhibition with a potent and selective monoclonal antibody that attenuates fibrosis effectively in vivo at clinically translatable exposures. Toxicology studies suggest that, as opposed to pan-TGF-β inhibitors, this anti-TGF-β3 antibody has a favorable safety profile for chronic administration., Conclusion: We establish a rationale for targeting TGF-β3 in SSc with a favorable therapeutic index., Funding: This study was funded by Genentech, Inc., Competing Interests: Declaration of interests All authors are current or past employees of Genentech, a member of the Roche group, and may hold Roche stock or stock options. A clinical trial sponsored by Genentech, Inc., with the indicated therapeutic agent is currently ongoing (ClinicalTrials.gov: NCT05462522). A patent application titled “Isoform-selective anti-TGF-beta antibodies and methods of use,” relating to the subject matter of this manuscript, has been provisionally filed by Genentech, Inc. Currently, J.R.A. is an employee of Sonoma Biotherapeutics, Z.H. is an employee of Gilead Sciences, Inc., and P.L. is an employee of Synthekine., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF